ライフサイエンスコーパス: mercaptopurine

1 eukemia (ALL) includes prednisone and oral 6-mercaptopurine.

2 dose, and all patients received daily oral 6-mercaptopurine.

3 mined the efficacy of dexamethasone and IV 6-mercaptopurine.

4 ectiveness of the immuno-suppressive agent 6-mercaptopurine.

5 S-methylation of thiopurine drugs such as 6-mercaptopurine.

6 rove on azathioprine but responded well to 6-mercaptopurine.

7 ed notable sensitivities to asparaginase and mercaptopurine.

8 ristine, L-asparaginase, methotrexate, and 6-mercaptopurine.

9 1.27 (95% CI, 0.48-3.39) for azathioprine/6-mercaptopurine.

10 treated with the thiopurines azathioprine or mercaptopurine.

11 ntenance with ATRA, oral methotrexate, and 6-mercaptopurine.

12 rapy comprising ATRA, oral methotrexate, and mercaptopurine.

13 lone or in combination with methotrexate and mercaptopurine.

14 ys 1 to 5, and a regimen of methotrexate and mercaptopurine.

15 ts a decreased V max and increased K m for 6-mercaptopurine.

16 sms in TPMT, can cause severe toxicity after mercaptopurine.

17 travenous methotrexate (1 g/m(2)) with daily mercaptopurine.

18 e mice were pretreated with leflunomide or 6-mercaptopurine.

19 , 11), whereas 6-thio NHD(+) (nicotinamide 6-mercaptopurine 5'-dinucleotide, 17) generates a cyclic d

20 their respective substrates, azathioprine/6-mercaptopurine, 5-fluorouracil and sulindac.

21 iving in extreme poverty were nonadherent to mercaptopurine (57.1% vs 40.9%); however, poor adherence

22 Although the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are well

23 first 16 months of continuation therapy with mercaptopurine (6-MP) and asparaginase (L-ASP).

24 he aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for th

25 The thiopurines azathioprine and 6-mercaptopurine (6-MP) are effective immune modulators an

26 Azathioprine (AZA) and 6-mercaptopurine (6-MP) are used in pediatric patients wit

27 Azathioprine and its metabolite 6-mercaptopurine (6-MP) are well established immunosuppres

28 kemia (ALL) are generally instructed to take mercaptopurine (6-MP) in the evening and without food or

29 6-Mercaptopurine (6-MP) is a nucleobase analog used in the

30 Clinical experience suggests that 6-mercaptopurine (6-MP) is effective therapy for children

31 ted AICAR production, or administration of 6-mercaptopurine (6-MP), a clinically approved inhibitor o

32 To evaluate potential toxicity of 6-mercaptopurine (6-MP), we reviewed the records of 485 pa

33 mong patients treated with azathioprine or 6-mercaptopurine (6-MP).

34 f immunomodulators [azathioprine (AZA), or 6-mercaptopurine (6-MP)] and newer biologic agents (inflix

35 lassified into a high DI phenotype (either 6-mercaptopurine [6-MP] or methotrexate [MTX] DI >=110% du

36 6-Mercaptopurine, 6-thioguanine and dasatinib are three im

37 ed for the simultaneously determination of 6-mercaptopurine, 6-thioguanine and dasatinib for the firs

38 for the selective and precise analysis of 6-mercaptopurine, 6-thioguanine and dasatinib in pharmaceu

39 ata revealed that the electro-oxidation of 6-mercaptopurine, 6-thioguanine and dasatinib is facilitat

40 at pH 8.0, the oxidation peak currents for 6-mercaptopurine, 6-thioguanine and dasatinib were found t

41 Compared with 6-mercaptopurine, 6-thioguanine causes excess toxicity wit

42 bolites of three clinically useful agents (6-mercaptopurine, 6-thioguanine, and Abacavir) can inhibit

43 Variability in prescribed doses of 6-mercaptopurine (6MP) and lack of adherence to a 6MP trea

44 6-Mercaptopurine (6MP) and methotrexate are the backbone o

45 Adequate exposure to oral 6-mercaptopurine (6MP) during maintenance therapy for chil

46 maintenance phase that includes daily oral 6-mercaptopurine (6MP).

47 ned either 6-thioguanine (750 patients) or 6-mercaptopurine (748 patients) during interim maintenance

48 ntenance therapy regimen included daily oral mercaptopurine (75 mg/m2) and weekly oral methotrexate (

49 lecular mechanism(s) of cellular response to mercaptopurine, a widely used antileukemic agent, we ass

50 azathioprine were superior to azathioprine/6-mercaptopurine: adalimumab (OR, 2.9; 95% CrI, 1.6-5.1),

51 In contrast, pretreatment of mice with 6-mercaptopurine, an inhibitor of de novo purine synthesis

52 ohn's disease were randomly assigned: 128 to mercaptopurine and 112 to placebo.

53 conferred resistance to chemotherapy with 6-mercaptopurine and 6-thioguanine when expressed in ALL l

54 he MRP4 drug resistance profile extends to 6-mercaptopurine and 6-thioguanine, two anticancer purine

55 d in the metabolism of thiopurines such as 6-mercaptopurine and 6-thioguanine.

56 an syndrome, the activator of the prodrugs 6-mercaptopurine and allopurinol, and a target for antipar

57 -TP) medications, including 6-thioguanine, 6-mercaptopurine and azathioprine, commonly used for immun

58 he immunosuppressive agents, azathioprine, 6-mercaptopurine and cyclosporine A, are compatible with p

59 lguanine, 8-azaguanine, 6-thioguanine, and 6-mercaptopurine and do not recognize any of the PurP liga

60 y 24 weeks of continuation chemotherapy with mercaptopurine and methotrexate.

61 -year treatment period with the following: 6-mercaptopurine and metronidazole [6MP/met] (comparator),

62 te the extensive clinical use and study of 6-mercaptopurine and other purine analogues, the cellular

63 types of adverse events were similar in the mercaptopurine and placebo groups.

64 g some of the antiproliferative effects of 6-mercaptopurine and potentially implicate Nurr1 as a mole

65 on of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plaus

66 The active metabolite of mercaptopurine and thioguanine (TG), deoxythioguanosine

67 Mercaptopurine and thioguanine are anticancer and immuno

68 armacokinetic and pharmacodynamic studies of mercaptopurine and thioguanine were done in Tpmt(-/-), T

69 Mercaptopurine and thioguanine, two of the most widely u

70 of TPMT on activation versus inactivation of mercaptopurine and thioguanine, we used a retroviral gen

71 ryl compounds, including medications such as mercaptopurine and thioguanine.

72 g setons, antibiotics, and azathioprine or 6-mercaptopurine and, in many cases, infliximab.

73 etabolites revealed elevated 6-MMP (6-methyl mercaptopurine) and low 6-TGN (6-thioguanine nucleotide)

74 andard dose of thiopurine (azathioprine or 6-mercaptopurine), and patients homozygous for a variant r

75 vement of guanylate kinase in 6-thioguanine, mercaptopurine, and abasic guanosine analog (e.g., ganci

76 hiopurines including 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine are effective anticance

77 ine drugs, including 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine, are widely employed an

78 ptions for 5-aminosalicylates azathioprine/6-mercaptopurine, and corticosteroids were extracted from

79 sessed the pharmacokinetics of methotrexate, mercaptopurine, and erythrocyte thioguanine nucleotide l

80 ians in optimizing therapeutic response to 6-mercaptopurine, and in identifying individuals at increa

81 % CI, 1.3-1.9]), and exposure to platinum, 6-mercaptopurine, and intrathecal chemotherapy, and a lowe

82 erapy followed by prednisone, vincristine, 6-mercaptopurine, and methotrexate (POMP) maintenance chem

83 otherapeutic agents, including asparaginase, mercaptopurine, and methotrexate.

84 city during consolidation therapy containing mercaptopurine, and remained significant in a multivaria

85 It is derived from 6-mercaptopurine, and these two drugs are often used inter

86 izing thiopurine therapy (i.e. azathioprine, mercaptopurine, and thioguanine).

87 th doxorubicin, vincristine, corticosteroid, mercaptopurine, and weekly high-dose asparaginase; and c

88 tarabine/etoposide; high-dose methotrexate/6-mercaptopurine; and daunorubicin, vincristine, prednison

89 Thioguanine and mercaptopurine are prodrugs requiring conversion into th

90 Azathioprine and 6-mercaptopurine are the standard maintenance therapies fo

91 nd Arg221, the only polar amino acids near 6-mercaptopurine, are highlighted as possible participants

92 ceptor Nurr1, interestingly, we identified 6-mercaptopurine as a specific activator of this receptor.

93 d following treatment with 10 daily doses of mercaptopurine at 100 mg/kg/d (0%, 68%, and 100% 50-day

94 resolution and the chemotherapeutic agent 6-mercaptopurine at 2.6 A resolution have been determined,

95 web-based randomisation system to oral daily mercaptopurine at a dose of 1 mg/kg bodyweight rounded t

96 of asparagine synthetase or treatment with 6-mercaptopurine attenuated the increased function of GLAS

97 ictor of outcome, but a direct comparison of mercaptopurine AUC in the remission and relapsed patient

98 A Cox regression analysis showed that mercaptopurine AUC was a marginally significant (P =.043

99 Thiopurine drugs (i.e., thioguanine [TG], mercaptopurine, azathioprine) are commonly used for the

100 the S-methylation (that is, inactivation) of mercaptopurine, azathioprine, and thioguanine and exhibi

101 patients are treated with standard doses of mercaptopurine, azathioprine, or thioguanine.

102 ntial 6-methylmercaptopurine production on 6-mercaptopurine/azathioprine (odds ratio, 3.0; 95% CI, 1.

103 6-Mercaptopurine/azathioprine alone and the addition of 6-

104 rticosteroids alone, 52 patients receiving 6-mercaptopurine/azathioprine alone or with corticosteroid

105 who were receiving corticosteroids and/or 6-mercaptopurine/azathioprine before surgery compared with

106 bowel disease receive corticosteroids and 6-mercaptopurine/azathioprine during elective bowel surger

107 adjusted odds ratio for patients receiving 6-mercaptopurine/azathioprine for any and major infectious

108 ine/azathioprine alone and the addition of 6-mercaptopurine/azathioprine for patients receiving corti

109 6-mercaptopurine/azathioprine is effective in IBD patients

110 ents receiving neither corticosteroids nor 6-mercaptopurine/azathioprine.

111 t an active site loop becomes ordered upon 6-mercaptopurine binding.

112 acid decreases V max and increases K m for 6-mercaptopurine but not K m for S-adenosyl- l-methionine.

113 xic effects of thiopurine prodrugs such as 6-mercaptopurine by methylating them in a reaction using S

114 We investigated whether mercaptopurine can prevent or delay postoperative clinic

115 ssant and anticancer drugs azathioprine or 6-mercaptopurine contains 6-thioguanine (6-TG).

116 We conclude that methylation of mercaptopurine contributes to the antiproliferative prop

117 Seven ALL drugs (asparaginase, prednisolone, mercaptopurine, dasatinib, nelarabine, daunorubicin, and

118 regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX

119 The effect of mercaptopurine did not significantly differ from placebo

120 to 10 pmol/g Hgb) and did not correlate with mercaptopurine dose or AUC.

121 undred ninety-one methotrexate doses and 190 mercaptopurine doses were monitored in 89 patients.

122 assignment was for daily oral or weekly IV 6-mercaptopurine during consolidation.

123 nosalicylate drugs as well as azothiaprine/6-mercaptopurine during pregnancy.

124 Mercaptopurine exhibited subtype-independent greater sen

125 teroids and/or cyclosporine, azathioprine, 6-mercaptopurine, FK-506, methotrexate) were identified an

126 n therapy with the same combinations, plus 6-mercaptopurine, for 12 months total treatment.

127 fter in vivo treatment with methotrexate and mercaptopurine given alone or in combination.

128 p analysis, three (10%) of 29 smokers in the mercaptopurine group and 12 (46%) of 26 in the placebo g

129 pared with 13 (13%) of 99 non-smokers in the mercaptopurine group and 14 (16%) of 86 in the placebo g

130 16 (13%) of patients in the mercaptopurine group versus 26 (23%) patients in the pla

131 treatment in 39 (30%) of 128 patients in the mercaptopurine group versus 41 (37%) of 112 in the place

132 topurine; however, patients assigned to IV 6-mercaptopurine had decreased survival after relapse.

133 6-mercaptopurine has been a standard component of long-ter

134 The thiopurines azathioprine and 6-mercaptopurine have been extensively prescribed as immun

135 EFS was similar with oral or IV 6-mercaptopurine; however, patients assigned to IV 6-merca

136 nferred comparable levels of resistance to 6-mercaptopurine in B-ALL cells both in vitro and in vivo.

137 ylates and 24.6% discontinued azathioprine/6-mercaptopurine in early pregnancy.

138 eport our experience with azathioprine and 6-mercaptopurine in patients with microscopic colitis.

139 potential benefit from the earlier use of 6-mercaptopurine in T-ALL therapy or the development of ad

140 = 39) comparing methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, certolizumab, ve

141 In addition, 6-mercaptopurine is a clinically important pro-drug that i

142 Mercaptopurine is an essential component of continuation

143 oietic toxicity in vivo after treatment with mercaptopurine is attenuated but not abolished by MSH2 d

144 Mercaptopurine is effective in preventing postoperative

145 es of the human polymorphism; indicates that mercaptopurine is more affected by the TPMT polymorphism

146 The purine anti-metabolite 6-mercaptopurine is one of the most widely used drugs for

147 nosuppressant thiopurines, azathioprine or 6-mercaptopurine, is associated with acute skin sensitivit

148 (TPMT) are known to have a marked effect on mercaptopurine metabolism and toxicity; however, some pa

149 rine methyl transferase and measurement of 6-mercaptopurine metabolites appear to be valuable for man

150 Studies of azathioprine and 6-mercaptopurine metabolites will make it easier and safer

151 95% CI, 1.17-2.58; P = .006), azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.61;

152 py, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inhib

153 f vincristine, adriamycin, prednisone, and 6-mercaptopurine (MP) and after continuous infusion of hig

154 ubstitution of oral 6-thioguanine (TG) for 6-mercaptopurine (MP) and triple intrathecal therapy (ITT)

155 Methotrexate (MTX) and mercaptopurine (MP) are widely used antileukemic agents

156 uorouracil, cytosine arabinoside (araC), and mercaptopurine (MP) demonstrated that Hmgb1(-/-) mouse e

157 (IBD), who have failed azathioprine (AZA) or mercaptopurine (MP) due to adverse events or suboptimal

158 Systemic exposure to mercaptopurine (MP) is critical for durable remissions i

159 Mercaptopurine (MP) is the mainstay of curative therapy

160 widely used antileukemic agent, we assessed mercaptopurine (MP) sensitivity in mismatch repair (MMR)

161 After mercaptopurine (MP) treatment (30 mg/kg/day for 14 days)

162 Thiopurines, including mercaptopurine (MP), 6-thioguanine ((S)G) and azathiopri

163 osed ALL after intravenous administration of mercaptopurine (MP).

164 ed with the combination of methotrexate plus mercaptopurine (MTX + MP).

165 -cell ALL included 2 years of treatment with mercaptopurine, MTX, vincristine, and prednisone (POMP).

166 Recent studies of azathioprine/6-mercaptopurine, nitroimidazole antibiotics, and inflixim

167 captopurine nucleotides from thioguanine and mercaptopurine nucleotides, respectively.

168 ower risk of isolated CNS relapse than did 6-mercaptopurine (odds ratio [OR] 0.53, 95% CI 0.30-0.92,

169 otrexate of at least 25 mg/m(2) per week and mercaptopurine of at least 75 mg/m(2) per day.

170 s in the azathioprine group were switched to mercaptopurine or methotrexate therapy because of intole

171 rexate sodium (OR, 0.60; 95% CI, 0.29-1.22), mercaptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycoph

172 s (OR, 3.4; 95% CI, 1.8-6.2), azathioprine/6-mercaptopurine (OR, 3.1; 95% CI, 1.7-5.5), and inflixima

173 rd, second-line (mycophenolate mofetil and 6-mercaptopurine) or third-line (tacrolimus or cyclosporin

174 xposed to 5-aminosalicylates, azathioprine/6-mercaptopurine, or corticosteroids during their first tr

175 iffered among genotypes after treatment with mercaptopurine (P < 0.0001 and P = 0.044, respectively)

176 Methotrexate and mercaptopurine plasma concentrations and erythrocyte thi

177 from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.

178 rine regulation of Nurr1 demonstrates that 6-mercaptopurine regulates Nurr1 through a region in the a

179 A detailed analysis of 6-mercaptopurine regulation of Nurr1 demonstrates that 6-m

180 tions in NT5C2 and a common determinant of 6-mercaptopurine resistance.

181 , was a substrate, and it was converted to 6-mercaptopurine ribonucleotide.

182 etabolites, thiouric acid (TU) and 2-amino-6-mercaptopurine riboside (6-TGR).

183 (p < 0.05) increased the S6-(4-nitrobenzyl)-mercaptopurine riboside (NBMPR) IC50 values by approxima

184 th trisomy of chromosomes 16 and 17, whereas mercaptopurine sensitivity was linked to gains of chromo

185 6-mercaptopurine should remain the thiopurine of choice fo

186 A metabolite of AZA, 6-mercaptopurine, still possessed this antiviral effect, b

187 contrast, TPMT+ cells were more sensitive to mercaptopurine than MOCK cells (IC(50) = 0.52 +/- 0.20 m

188 inhibitor in combination with azathioprine/6-mercaptopurine therapy (odds ratio [OR], 1.74; 95% CI, 1

189 bo-controlled trial reported the efficacy of mercaptopurine therapy for children newly diagnosed with

190 nhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathi

191 nces the risk of GI toxicity associated with mercaptopurine therapy.

192 Thiopurines (azathioprine, mercaptopurine, thioguanine) and methotrexate are widely

193 ancer treatment (capecitabine, fluorouracil, mercaptopurine, thioguanine, irinotecan).

194 adenosyl- l-homocysteine and the substrate 6-mercaptopurine, to 1.8 and 2.0 A resolution, respectivel

195 identify additional genetic determinants of mercaptopurine toxicity, a genome-wide analysis was perf

196 with wild-type TPMT develop toxicity during mercaptopurine treatment for reasons that are not well u

197 econd DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM

198 ved 30 courses of maintenance therapy with 6-mercaptopurine, vincristine, methotrexate, and prednison

199 ars post-CR date, alternated three cycles of mercaptopurine, vincristine, methotrexate, and prednison

200 lternating blocks of three cycles of POMP (6-mercaptopurine, vincristine, methotrexate, and prednison

201 aintenance therapy with dose-reduced POMP (6-mercaptopurine, vincristine, methotrexate, and prednison

202 The higher sensitivity of TPMT+ cells to mercaptopurine was associated with higher concentrations

203 ce chemotherapy with oral methotrexate and 6-mercaptopurine was continued for 30 months.

204 used antileukemic agents (eg, methotrexate, mercaptopurine), we determined the rate of DNPS and the

205 that 6-thioguanine is more effective than 6-mercaptopurine, we compared the efficacy and toxicity of

206 xhibited a haploinsufficient phenotype after mercaptopurine, whereas haploinsufficiency was less prom

207 The prodrugs azathioprine and 6-mercaptopurine, which are well-established anticancer an

208 dnisone and for intravenous (IV) over oral 6-mercaptopurine, which remain to be validated.

209 particular sensitivities to asparaginase and mercaptopurine, with chromosome-specific associations.

210 ient response to the chemotherapeutic drug 6-mercaptopurine, with some model parameters being patient

211 with NT5C2 mutations are chemoresistant to 6-mercaptopurine yet show impaired proliferation and self-